MKI67

Proliferation marker protein Ki-67 · P46013 · MKI67 on Sugi Atlas →

0 patent compounds predicted against MKI67, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to MKI67 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Micronized Progesterone Versus Norethisterone Acetate in Combination With Estrogen as Menopausal Hormone Therapy PHASE3RECRUITING
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia PHASE2COMPLETED
Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer PHASE2COMPLETED
Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance PHASE2COMPLETED
Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer PHASE2COMPLETED
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy PHASE2COMPLETED
MRI in Predicting Tumor Reponse After Radiofrequency Ablation in Women With Invasive Breast Cancer PHASE2WITHDRAWN
18F-FLT-PET in Breast Cancer (MK-0000-139) PHASE2COMPLETED
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma PHASE2COMPLETED
Capecitabine in Low Risk Triple Negative Breast Cancer PHASE2NOT_YET_RECRUITING
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer PHASE1COMPLETED
Tamoxifen in Patients With Oesophageal Cancer PHASE1UNKNOWN
Study of Tissue and Blood Samples From Patients With Low-Grade Glioma nanCOMPLETED
Prospective Breast Cancer Biobanking nanENROLLING_BY_INVITATION
Comparison of Morphometric Assessment Using Methyl Green Pyronin and AgNOR Staining of Oral Squamous Cell Carcinoma nanUNKNOWN
Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B. nanCOMPLETED
Identification and Semi-Quantification of Ki-67 Protein Expression Status nanCOMPLETED
The Use of Immunohistochemical Staining for the Prediction of Wilms Tumour Progression and Recurrence nanUNKNOWN
Re-Evaluation of Tumor Samples From Women With Breast Cancer With the in Vitro Diagnostic Kit MammaTyperTM nanCOMPLETED
Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors nanACTIVE_NOT_RECRUITING
Screening Triage and Risk Stratification nanRECRUITING
Usefulness of Ki67 Index in Hormone Receptor-positive Breast Cancer nanCOMPLETED
PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast Cancer nanCOMPLETED
Multi-point Intra-mucosal Injections of Cross-linked Hyaluronic Acid (DESIRIAL®) in the Vaginal Vestibule nanCOMPLETED
Conservative Management of CIN2 Lesions and Biomarkers Evaluation nanCOMPLETED
Expression of Different Proliferation Biomarkers in Adreno-cortical Tumors nanUNKNOWN
Cohort of Well-differentiated Grade 3 Neuroendocrine Digestive Tumors nanCOMPLETED
Tissue- and Serum-Derived Exosomal microRNAs as Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer nanNOT_YET_RECRUITING
Multimodal Project nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a MKI67 binder may also engage these)

ProteinNameSimilarity
CDCA2 Cell division cycle-associated protein 2 1.000 landscape →
Q86XD8 0.998 Q86XD8 →
TET1 Methylcytosine dioxygenase TET1 0.997 landscape →
Q3V0A6 0.997 Q3V0A6 →
Q9Y2F5 0.997 Q9Y2F5 →
Q4QY64 0.997 Q4QY64 →
B4IH30 0.997 B4IH30 →
Q9GSR1 0.996 Q9GSR1 →
O35923 0.996 O35923 →
E9Q5F9 0.996 E9Q5F9 →
ATAD5 ATPase family AAA domain-containing protein 5 0.996 landscape →
E1BC15 0.996 E1BC15 →
Q8IYL3 0.995 Q8IYL3 →
SETD2 Histone-lysine N-methyltransferase SETD2 0.995 landscape →
E9Q286 0.995 E9Q286 →
A4IGL8 0.995 A4IGL8 →
O54963 0.995 O54963 →
Q3URK3 0.995 Q3URK3 →
Q8L7I1 0.995 Q8L7I1 →
Q703I1 0.995 Q703I1 →
Q5RD08 0.995 Q5RD08 →
A6NCI8 0.995 A6NCI8 →
Q569L8 0.995 Q569L8 →
P49452 0.994 P49452 →
Q6NS59 0.994 Q6NS59 →
E9PVX6 0.994 E9PVX6 →
Q949U2 0.994 Q949U2 →
P70486 0.994 P70486 →
A6NKB5 0.994 A6NKB5 →
Q9D9W6 0.994 Q9D9W6 →